Pharmaceutical

MASH revival with over $2.5bn for innovator drug partnership deals in 2024

MASH innovator drugs witnessed an over $2.5bn increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD).

Apr 3, 2024 - 00:00
MASH revival with over $2.5bn for innovator drug partnership deals in 2024
MASH innovator drugs witnessed an over $2.5bn increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD).
Read the original article

Tags:

Previous Article

A proactive, data-driven approach to closing care gaps in heart disease

Next Article

Ipsen joins the ADC club with deal worth up to $900m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan...

Oct 20, 2024

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell...

Sep 10, 2024

STAT+: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling

STAT+: ‘It’s a nightmare’: One of the most common child...

Mar 4, 2024